BioPharma Resources

Drug Trial Radar · NCT05347485

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

86

Actual

Start

May 13, 2022

Primary completion

Nov 30, 2023

Study completion Dec 15, 2023

Sponsor

Lead sponsor
Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).

Conditions

  • Multiple Myeloma

Interventions

  • Cilta-celDrug

    Cilta-cel will be administered as an IV infusion.

  • Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)Drug

    Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: From Day 1 (post infusion) up to 18.6 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of California San Francisco

    San Francisco, California

  • Stanford University Medical Center

    Stanford, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Kansas University Medical Center

    Westwood, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University School Of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Mount Sinai Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.